May 19, 2021 Preliminary 2-year results from the single-arm CLASP study show that mitral valve repair using the Pascal transcatheter system is associated with high rates of survival and freedom from rehospitalization as well as a durable reduction in mitral regurgitation (MR). According to Molly Szerlip, MD (Baylor Scott & White Health, Plano, TX), who virtually presented the study as a late breaker at EuroPCR 2021, the data look “extremely good,” at least for the numbers of patients followed so far, in both functional and degenerative MR. “This reiterates that this is an excellent device and one that needs to be out on the market,” she told TCTMD. “And as the long-term data come out, there's nothing that would make us think that [this device] is not going to continue to have excellent long-term outcomes.”